Evidence map›Paper›PMID 19534628›Full record

Trial reportAIDS research and human retroviruses2009

Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.

Bret J Rudy, John Sleasman, Bill Kapogiannis, Craig M Wilson, James Bethel, Leslie Serchuck, Sushma Ahmad, Coleen K Cunningham, Adolescent Trials Network for HIV/AIDS Interventions

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in AIDS research and human retroviruses, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04281459 (Short Cycle Therapy in ART Regimens Containing Rilpivirine), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04281459 nacompletednot on this mapstarted 2020, after this paper: background citation

Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2020 to 2020Enrolled33ConditionsHIV-1-infectionArmsHIV Treatment Satisfaction Questionnaire status
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bret J RudyCraig Dalsimer Division of Adolescent Medicine, Children's Hospital of Philadelphia, 3535 Market Street, Suite 1517, Philadelphia, PA 19104, USA. rudy@email.chop.edu
John Sleasman
Bill Kapogiannis
Craig M Wilson
James Bethel
Leslie Serchuck
Sushma Ahmad
Coleen K Cunningham
Adolescent Trials Network for HIV/AIDS Interventions

Funding

Adol. Medicine Trials Network for HIV/AIDS InterventionsU01HD040474 · NICHD · WESTAT, INC. · PI HARRIS, DONALD ROBERT · 2001 to 2016
$114.4M
LEADERSHIP GROUP FOR ADOLESCENT MEDICINE TRIALS NETWORKU01HD040533 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, CRAIG M · 2001 to 2016
$76.4M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
ZAP-70 EXPRESSION, CD38 EXPRESSION AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIAM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI HINDS, PAMELA S · 2005 to 2010
$13.8M
IMPACT OF HIV-1 GENOTYPE ON THERAPY RESPONSE IN CHILDRENR01AI047723 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI SLEASMAN, JOHN W. · 2001 to 2010
$3.3M
NCRR NIH HHS 5-M01-RR-020359-04NCRR NIH HHS UL1-RR-024134NIAID NIH HHS R01 AI047723NICHD NIH HHS U01 HD 040474NICHD NIH HHS U01 HD040474NICHD NIH HHS U01 HD 040533NICHD NIH HHS U01 HD040533PHS HHS U01-A141089
6 · The paper itself

Abstract

This was a proof-of-principle study to evaluate the impact of short cycle therapy (SCT; 4 days on/3 days off) in adolescents and young adults with good viral suppression on a protease inhibitor-based antiretroviral regimen. Subjects were recruited by the Adolescent Trials Network for HIV/AIDS Interventions and the Pediatric AIDS Clinical Trials Group. Subjects were infected either through perinatal/early childhood transmission or later via risk behaviors. All subjects were required to have at least 6 months of documented viral suppression below 400 copies/ml plus a preentry value below 200 copies/ml and an entry CD4+ T cell count above 350 cells/mm3. Of the 32 subjects enrolled, 12 (37.5%) had confirmed viral load rebound >400 copies, with 18 subjects (56%) coming off for any reason. The majority of subjects resuppressed when placed back onto continuous therapy using the same agents. Although no difference was found in virologic rebound rates between the early and later transmission groups, those infected early in life had higher rates of coming off SCT for any reason. There was no impact of SCT on the CD4+ T cell counts in those who remained on study or those who came off SCT for any reason. Subjects demonstrated good adherence to the SCT regimen. This study suggests that further evaluation of SCT may be warranted in some groups of adolescents and young adults infected with HIV.

Indexed as

Viral LoadAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIV InfectionsHumansPatient ComplianceTreatment OutcomeYoung AdultAnti-HIV Agents

Identifiers

PMID19534628
PMCPMC2853866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.